glp-1 obesity drug news today Study predicts 16 new drugs may come to market Weight Loss - ABC7 New

Three-year outcomes of post-acute sequelae of COVID-19

Seek medical advice if fatigue: Persists beyond several months without improvement, despite adequate nutrition and hydration Worsens progressively or becomes debilitating, significantly impairing daily activities or work capacity Is accompanied by severe or persistent gastrointestinal symptoms (intractable nausea, vomiting, diarrhoea, abdominal pain) Occurs alongside signs of dehydration (dark urine, dizziness, reduced urine output, dry mouth) Is associated with symptoms of hypoglycaemia (tremor, sweating, confusion, palpitations), particularly in patients taking concurrent insulin or sulphonylureas Urgent medical attention is required if patients experience: Severe abdominal pain , especially if radiating to the back, which may indicate pancreatitisa rare but serious adverse effect of GLP-1 medications

Clin Toxicol (Phila) 2008;46(4):346347

We excluded 40 individuals who were already using insulin, 44 who started insulin therapy after discontinuing GLP-1 receptor agonists, and 70 with missing baseline or follow-up HbA1c values